FIELD: pharmaceutical industry, medicine.
SUBSTANCE: invention relates to human insulin drug with activity of 100 IU/ml, including cartridge forms. Drug contains active ingredient, glycerol as isotonic agent, conserving agent and water, wherein it contains human insulin substance of high purity with residual proteolysis activity not more than 0.005 adsorption units, sodium chloride as additional isotonic agent, m-cresol as conserving agent, and additionally sodium dihydrogenphosphate dihydrate or disodium hydrogenphosphate heptahydrate as substance with buffer capacity and pH 6.9-7.8.
EFFECT: human insulin drug of short action with increased physiological activity and physical and chemical storage stability.
6 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN INSULIN DRUG OF DURABLE ACTION | 2003 |
|
RU2252753C2 |
| METHOD FOR PREPARING READY MEDICINAL FORMULATION OF INSULIN WITH SHORT EFFECT | 2002 |
|
RU2261107C2 |
| METHOD FOR PREPARING HUMAN INSULIN COMBINED PREPARATION | 2002 |
|
RU2261108C2 |
| METHOD FOR PRODUCTION OF INSULIN DRUG OF DURABLE ACTION | 2002 |
|
RU2252782C2 |
| METHOD FOR PRODUCTION OF PHARMACEUTICAL COMPOSITION SOLUTION BASED ON SUBSTANCE OF HUMAN GENE ENGINEERED (RECOMBINANT) INSULIN | 2004 |
|
RU2275189C1 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION SUSPENSION BASED ON SUBSTANCE OF HUMAN GENETIC ENGINEERING (RECOMBINANT) INSULIN | 2004 |
|
RU2281756C2 |
| METHOD OF PREPARING PHARMACEUTICAL COMPOSITION SOLUTION BASED ON SUBSTANCE OF GENE ENGINEERING (RECOMBINANT) HUMAN INSULIN | 2001 |
|
RU2184533C1 |
| METHOD OF OBTAINING INSULIN ZINC COMPLEXES | 2011 |
|
RU2572214C2 |
| STABLE COMPOSITION OF INSULIN GLULISIN | 2014 |
|
RU2691059C2 |
| PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES | 2004 |
|
RU2421238C2 |
